Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CORRECT-MRD I: First Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease

NCT06398743 is registered in ClinicalTrials.gov with Exact Sciences Corporation as lead sponsor.

NCT NCT06398743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06398743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CORRECT-MRD I: First Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
Lead sponsor
Exact Sciences Corporation
Phase
Observational
Overall status
Active, not recruiting
Start date
June 20, 2023
Completion date
December 31, 2027
Enrollment
416 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer